Clinical trial
Maintenance Therapy Using Lenalidomide in Myeloma
NCT00430365 · University Hospital, Toulouse, Other · Completed
Key facts
| NCT number | NCT00430365 |
|---|---|
| Title | Maintenance Therapy Using Lenalidomide in Myeloma |
| Official title | Relevance of Maintenance Therapy Using Lenalidomide (Revimid®) After Autologous Stem Cell Transplantation Patients Under the Age Of 65. (Open, Randomised, Multi-centric Trial Versus Placebo). |
| Acronym | IFM2005-02 |
| Lead sponsor | University Hospital, Toulouse, Other |
| Collaborators | Intergroupe Francophone du Myelome Celgene Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Myeloma |
| Intervention type | Drug |
| Interventions | lenalidomide, placebo |
| Enrollment | 614 |
| Start date | Jun 1, 2006 |
| Primary completion | Sep 1, 2017 |
| Completion | Sep 1, 2018 |
| First posted | Feb 1, 2007 |
| Last update posted | Apr 26, 2019 |
| Countries | Belgium, France, Switzerland |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: